Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 5% following positive data from its oral GLP-1 drug ASC30 for obesity treatment in a Phase IIa study in the U.S. [1] Group 1: Stock Performance - Gilead Sciences-B's stock increased by 5.12%, reaching HKD 13.56, with a trading volume of HKD 13.2847 million [1]. Group 2: Research and Analyst Opinions - Citigroup released a report indicating that the data from ASC30 demonstrates its potential as a best-in-class treatment, enhancing confidence in future collaborations and predicting a positive stock price reaction; they reiterated a "Buy/High Risk" rating with a target price of HKD 32 [1]. - Orient Securities noted that ASC30's weight loss data is superior, with good safety profiles, and the molecular patent has been authorized in the U.S., indicating significant business development potential [1]. Group 3: Drug Development Insights - ASC30, developed on the Ultra-Long-Acting Platform (ULAP), has subcutaneous injection formulations with apparent half-lives of 46 days and 75 days, significantly longer than other ultra-long-acting GLP-1 drugs, while also demonstrating superior safety [1].
歌礼制药-B午前拉升逾5% ASC30竞争优势显著 机构称其BD潜力较大